Navigation Links
Molecular Diagnostics: Technologies, Markets and Companies - 2013 Report
Date:7/25/2013

DUBLIN, July 25, 2013 /PRNewswire/ --

Research and Markets (http://www.researchandmarkets.com/research/7l6fw7/molecular) has announced the addition of the new report "Molecular Diagnostics - Technologies, Markets and Companies" to their offering.

     (Logo: http://photos.prnewswire.com/prnh/20130307/600769)

This report describes and evaluates the molecular diagnostics technologies that will play an important role in practice of medicine, public health, pharmaceutical industry, forensics and biological warfare in the 21st century. This includes several polymerase chain reactions (PCR)-based technologies, fluorescent in situ hybridization (FISH), peptide nucleic acids (PNA), electrochemical detection of DNA, sequencing, mitochondrial DNA, biochips, nanotechnology and proteomic technologies.

Initial applications of molecular diagnostics were mostly for infections but are now increasing in the areas of genetic disorders, preimplantation screening and cancer. Genetic screening tests, despite some restrictions, is a promising area for future expansion of in vitro diagnostic market. Molecular diagnostics is being combined with therapeutics and forms an important component of integrated healthcare. Molecular diagnostic technologies are also involved in development of personalized medicine based on pharmacogenetics and pharmacogenomics. Currently, there has been a considerable interest in developing rapid diagnostic methods for point-of-care and biowarfare agents such as anthrax.

The number of companies involved in molecular diagnostics has increased remarkably during the past few years. More than 800 companies have been identified to be involved in developing molecular diagnostics and 333 of these are profiled in the report along with tabulation of 779 collaborations. Despite the strict regulation, most of the development in molecular diagnostics has taken place in the United States, which has the largest number of companies.

The markets for molecular diagnostics technologies are difficult to estimate. Molecular diagnostics markets overlap with markets for non-molecular diagnostic technologies in the in vitro diagnostic market and are less well defined than those for pharmaceuticals. Molecular diagnostic markets are analyzed for 2012 according to technologies, applications and geographical regions. Forecasts are made up to 2022. A major portion of the molecular diagnostic market can be attributed to advances in genomics and proteomics. Biochip and nanobiotechnology are expected to make a significant contribution to the growth of molecular diagnostics.

Benefits of this report

- This report has evolved during the past 17 years, profiting from feedback by numerous readers and experts.

- The most comprehensive and up-to-date one-stop source of information on technical and commercial aspects of molecular diagnostics.

- Includes profiles of 333 companies, the largest number in any report on this topic.

- 600 references, cited in the report are included in the bibliography.

- The text is supplemented by 101 tables and 16 figures.

Who should read this report?

- Chief executive officers of molecular diagnostic companies.

- Business development executives of pharmaceutical and biotechnology companies.

- Executives of companies involved in developing integration of diagnosis and treatment as well as those interested in personalized medicine.

- Officers of genomic and proteomic companies interested in diagnostic technologies.

- Research scientists involved in application of molecular diagnostic technologies.

- Planners of healthcare services.

Key Topics Covered:

Part I: Technologies & Applications

Executive Summary

1. Introduction

2. Molecular Diagnostic Technologies

3. Biochips, Biosensors, and Nanobiotechnology

4. Proteomic Technologies for Molecular Diagnostics

5. Molecular Diagnosis of Genetic Disorders

6. Molecular diagnosis of cardiovascular disorders

7. Molecular Diagnosis of Infections

8. Molecular Diagnosis of Cancer

9. Molecular Diagnostics in Biopharmaceutical Industry & Healthcare

10. Molecular Diagnostics in Forensic Medicine and Biological Warfare

11. References

Part II: Regulations, Markets & Companies

12. Ethics, Patents and Regulatory issues

13. Markets for Molecular Diagnostics

14. Companies involved in molecular diagnostics

For more information visit http://www.researchandmarkets.com/research/7l6fw7/molecular

Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com
U.S. Fax: +1-646-607-1907
Fax (outside U.S.): +353-1-481-1716
Sector: Diagnostics


'/>"/>
SOURCE Research and Markets
Copyright©2012 PR Newswire.
All rights reserved

Related biology technology :

1. Molecular Biomarkers for Cancer Detection and Management
2. Managing Antibiotic-Resistant Bloodstream Infections with Rapid Molecular Diagnostics educational webinar hosted by Nanosphere and Xtalks
3. The Pistoia Alliance Releases HELM Biomolecular Representation Standard Open Source Tools
4. NuView Life Sciences Announces Presentation of Data for Novel Prostate and Bladder Cancer Molecular Diagnostic at SNMMI
5. Understanding the molecular mechanisms underlying Alzheimers disease
6. Rosetta Genomics Announces Acceptance for Publication by Molecular Cancer of Rosetta Cancer Origin Test Manuscript
7. Caris Life Sciences ASCO Presentation Highlights the Utility of Molecular Profiling for the Management of Rare and Aggressive Cancers
8. Maryville, Tennessee Based Molecular Pathology Laboratory Network (MPLN) Celebrates 38th Annual Medical Laboratory Professional Week by Honoring Employees
9. Researchers untangle molecular pathology of giant axonal neuropathy
10. Isothermal Nucleic Acid Amplification Technologies Market 2012-2017: Molecular Diagnostics, Infectious Disease Testing, Blood Screening, Cancer Research, Rapid Testing
11. Molecular Recognition Elements in Sensing Applications - Biodetection Technologies 2013
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/9/2017)... , Oct. 9, 2017  BioTech Holdings ... mechanism by which its ProCell stem cell therapy ... limb ischemia.  The Company, demonstrated that treatment with ... of limbs saved as compared to standard bone ... molecule HGF resulted in reduction of therapeutic effect.  ...
(Date:10/9/2017)... ... 2017 , ... The Giving Tree Wellness Center announces the ... of consumers who are incorporating medical marijuana into their wellness and health regimens. ... operators of two successful Valley dispensaries, The Giving Tree’s two founders, Lilach Mazor ...
(Date:10/7/2017)... ... October 06, 2017 , ... ... ProxiMeta™ Hi-C metagenome deconvolution product, featuring the first commercially available Hi-C kit. ... to perform Hi-C metagenome deconvolution using their own facilities, supplementing the company’s ...
(Date:10/6/2017)... ... October 06, 2017 , ... On Tuesday, ... webinar on INSIGhT, the first-ever adaptive clinical trial for glioblastoma (GBM). The featured ... event is free and open to the public, but registration is required. , ...
Breaking Biology Technology:
(Date:4/11/2017)... , April 11, 2017 NXT-ID, Inc. ... technology company, announces the appointment of independent Directors Mr. ... to its Board of Directors, furthering the company,s corporate governance ... Gino ... we look forward to their guidance and benefiting from their ...
(Date:4/4/2017)... 2017   EyeLock LLC , a leader of ... States Patent and Trademark Office (USPTO) has issued U.S. ... of an iris image with a face image acquired ... company,s 45 th issued patent. ... given the multi-modal biometric capabilities that have recently come ...
(Date:3/29/2017)... 2017  higi, the health IT company that operates ... America , today announced a Series B investment ... EveryMove. The new investment and acquisition accelerates higi,s strategy ... transform population health activities through the collection and workflow ... higi collects and secures data today on behalf of ...
Breaking Biology News(10 mins):